Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

STADA Arzneimittel AG

https://www.stada.com/

Latest From STADA Arzneimittel AG

Stada And Alvotech Eye Launch Date For Ustekinumab After EU Approval

Stada has revealed details of exactly when in 2024 it plans to launch its Alvotech-partnered Uzpruvo ustekinumab biosimilar to Stelara, having just been granted a pan-European marketing authorization. At the same time, the German firm has also struck a distribution deal for prescription and consumer healthcare products with Zuellig in the Philippines.

Biosimilars Approvals

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

M & A Deals

Stada Grows China Presence Through CR Sanjiu Partnership

Stada has struck a deal with CR Sanjiu for distribution and promotion of its cough and cold brands after identifying expansion in the Chinese market as a key strategic target.

Deals Strategy

Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023

“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.

C-Suite Speaks Commercial Strategies
See All

Company Information

UsernamePublicRestriction

Register